Total Funding
1
Total FundingConvertible Note raised
Growth Score
pts
Heat Score
-3 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
4786912
Signal Genetics, Inc., is a commercial-stage, molecular diagnostics company providing innovative diagnostic services.
Acquired by 
Viridian Therapeutics
Richard A. Bender: Chief Medical Officer
About the Company
Signal Genetics, Inc., is a commercial-stage, molecular diagnostics company providing innovative diagnostic services that help physicians make better-informed decisions concerning the care of their patients suffering from cancer.
The company was founded in April 2010 after becoming the exclusive licensee to the world-renowned research on
multiple myeloma performed at the University of Arkansas for Medical Sciences (UAMS). More than 30 years of clinical research on nearly 10,000 multiple myeloma patients who received their care at UAMS went into the development of Signal Genetics’ flagship product, MyPRS® (Myeloma Prognostic Risk Signature).
